Ontology highlight
ABSTRACT: Objective
To assess the role of dutasteride in preventing clinical progression of benign prostatic hyperplasia in asymptomatic men with larger prostates.Design
Post hoc analysis of four year, double blind Reduction by Dutasteride of Prostate Cancer Events (REDUCE) studyParticipants
1617 men randomised to dutasteride or placebo with a prostate size >40 mL and baseline International Prostate Symptom Score (IPSS) <8. Subjects who took medications for benign prostatic hyperplasia were excluded at study entry.Interventions
Placebo or dutasteride 0.5 mg daily.Main outcome measures
Comparison of risk of clinical progression of benign prostatic hyperplasia at four years (defined as a ≥ 4 point worsening on IPSS, acute urinary retention, urinary tract infecti
SUBMITTER: Toren P
PROVIDER: S-EPMC3626257 | biostudies-literature | 2013 Apr
REPOSITORIES: biostudies-literature